FDA delays Capricor's deramiocel PDUFA date to review new data
The FDA is pushing back its decision on Capricor Therapeutics’ problematic Duchenne muscular dystrophy therapy to review additional data for a more niche indication. The company on Monday said the agency has extended the PDUFA ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.